Literature DB >> 21088257

Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.

Mohamed A Elmeliegy1, Angel M Carcaboso, Michael Tagen, Feng Bai, Clinton F Stewart.   

Abstract

PURPOSE: To study the role of drug transporters in central nervous system (CNS) penetration and cellular accumulation of erlotinib and its metabolite, OSI-420. EXPERIMENTAL
DESIGN: After oral erlotinib administration to wild-type and ATP-binding cassette (ABC) transporter-knockout mice (Mdr1a/b(-/-), Abcg2(-/-), Mdr1a/b(-/-)Abcg2(-/-), and Abcc4(-/-)), plasma was collected and brain extracellular fluid (ECF) was sampled using intracerebral microdialysis. A pharmacokinetic model was fit to erlotinib and OSI-420 concentration-time data, and brain penetration (P(Brain)) was estimated by the ratio of ECF-to-unbound plasma area under concentration-time curves. Intracellular accumulation of erlotinib was assessed in cells overexpressing human ABC transporters or SLC22A solute carriers.
RESULTS: P(Brain) in wild-type mice was 0.27 ± 0.11 and 0.07 ± 0.02 (mean ± SD) for erlotinib and OSI-420, respectively. Erlotinib and OSI-420 P(Brain) in Abcg2(-/-) and Mdr1a/b(-/-)Abcg2(-/-) mice were significantly higher than in wild-type mice. Mdr1a/b(-/-) mice showed similar brain ECF penetration as wild-type mice (0.49 ± 0.37 and 0.04 ± 0.02 for erlotinib and OSI-420, respectively). In vitro, erlotinib and OSI-420 accumulation was significantly lower in cells overexpressing breast cancer resistance protein (BCRP) than in control cells. Only OSI-420, not erlotinib, showed lower accumulation in cells overexpressing P-glycoprotein (P-gp) than in control cells. The P-gp/BCRP inhibitor elacridar increased erlotinib and OSI-420 accumulation in BCRP-overexpressing cells. Erlotinib uptake was higher in OAT3- and OCT2-transfected cells than in empty vector control cells.
CONCLUSION: Abcg2 is the main efflux transporter preventing erlotinib and OSI-420 penetration in mouse brain. Erlotinib and OSI-420 are substrates for SLC22A family members OAT3 and OCT2. Our findings provide a mechanistic basis for erlotinib CNS penetration, cellular uptake, and efflux mechanisms. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21088257      PMCID: PMC3017236          DOI: 10.1158/1078-0432.CCR-10-1934

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

1.  Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents.

Authors:  Chun-Jung Lin; Ying Tai; Miao-Tzu Huang; Yuan-Feen Tsai; Hao-Jui Hsu; Kai-Yuan Tzen; Horng-Huei Liou
Journal:  J Neurochem       Date:  2010-05-06       Impact factor: 5.372

2.  Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier.

Authors:  Ryota Kikuchi; Hiroyuki Kusuhara; Daisuke Sugiyama; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2003-04-08       Impact factor: 4.030

3.  Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.

Authors:  Shinobu Mori; Hitomi Takanaga; Sumio Ohtsuki; Tsuneo Deguchi; Young-Sook Kang; Ken-Ichi Hosoya; Tetsuya Terasaki
Journal:  J Cereb Blood Flow Metab       Date:  2003-04       Impact factor: 6.200

4.  Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability.

Authors:  F Stain-Texier; G Boschi; P Sandouk; J M Scherrmann
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

5.  Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.

Authors:  P Arndt; C Volk; V Gorboulev; T Budiman; C Popp; I Ulzheimer-Teuber; A Akhoundova; S Koppatz; E Bamberg; G Nagel; H Koepsell
Journal:  Am J Physiol Renal Physiol       Date:  2001-09

6.  Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus.

Authors:  Yoshinori Nagata; Hiroyuki Kusuhara; Hitoshi Endou; Yuichi Sugiyama
Journal:  Mol Pharmacol       Date:  2002-05       Impact factor: 4.436

7.  Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF.

Authors:  Markos Leggas; Yanli Zhuang; Jonathan Welden; Zack Self; Christopher M Waters; Clinton F Stewart
Journal:  J Pharm Sci       Date:  2004-09       Impact factor: 3.534

8.  Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.

Authors:  Markos Leggas; Masashi Adachi; George L Scheffer; Daxi Sun; Peter Wielinga; Guoqing Du; Kelly E Mercer; Yanli Zhuang; John C Panetta; Brad Johnston; Rik J Scheper; Clinton F Stewart; John D Schuetz
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

9.  Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3.

Authors:  Martina Hayer-Zillgen; Michael Brüss; Heinz Bönisch
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

10.  Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.

Authors:  Ming Zhao; Ping He; Michelle A Rudek; Manuel Hidalgo; Sharyn D Baker
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-08-15       Impact factor: 3.205

View more
  37 in total

1.  Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model.

Authors:  Mohamed A Elmeliegy; Angel M Carcaboso; Lionel M L Chow; Ziwei M Zhang; Christopher Calabrese; Stacy L Throm; Fan Wang; Suzanne J Baker; Clinton F Stewart
Journal:  J Pharm Sci       Date:  2011-08-11       Impact factor: 3.534

Review 2.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

Review 3.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.

Authors:  Manmeet S Ahluwalia; Kevin Becker; Benjamin P Levy
Journal:  Oncologist       Date:  2018-04-12

Review 4.  Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.

Authors:  Grainne M O'Kane; Natasha B Leighl
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

5.  Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.

Authors:  Arkadiusz Z Dudek; Ahmad Raza; Ming Chi; Meghali Singhal; Rajneet Oberoi; Rajendar K Mittapalli; Sagar Agarwal; William F Elmquist
Journal:  Clin Genitourin Cancer       Date:  2012-12-21       Impact factor: 2.872

Review 6.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

Review 7.  Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.

Authors:  K Mandery; H Glaeser; M F Fromm
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

8.  Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.

Authors:  Masahide Fukudo; Yasuaki Ikemi; Yosuke Togashi; Katsuhiro Masago; Young Hak Kim; Tadashi Mio; Tomohiro Terada; Satoshi Teramukai; Michiaki Mishima; Ken-Ichi Inui; Toshiya Katsura
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

9.  Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Authors:  Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

10.  Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.

Authors:  Ramola Sane; Rajendar K Mittapalli; William F Elmquist
Journal:  J Pharm Sci       Date:  2013-01-18       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.